


ABSTRACT


The present invention has as its object providing substituted phenethylamine derivatives that function as a motilin receptor antagonist and which are useful as medicines.

The invention provides compounds of Formula (1):



wherein:

Cy is a group of Formula (2):



an optionally substituted heterocyclic ring, C₃₋₇cycloalkyl or phenyl;

R₁, R₂, R₃, R₄ and R₅ are hydrogen, halogen, hydroxy, amino, trifluoromethyl or nitrile and at least one of R₁,

R₂, R₃, R₄ and R₅ is halogen, trifluoromethyl or nitrile;

R₆ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, amino or hydroxy;

R₇ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, optionally substituted amino or hydroxy;

R₈ is hydrogen, methyl or ethyl;

R₉ is optionally substituted straight-chained or branched C₁₋₆alkyl, optionally substituted straight-chained or branched C₂₋₆alkenyl, optionally substituted straight-chained or branched C₂₋₆alkynyl, C₃₋₇cycloalkyl or
 5 optionally substituted phenyl;


R₂₀ is hydrogen or straight-chained or branched C₁₋₃alkyl or R₉ and R₂₀ may together form C₃₋₇cycloalkyl;

R₁₀ is hydrogen or straight-chained or branched C₁₋₃alkyl;

10 R₁₁ is hydrogen, optionally substituted straight-chained or branched C₁₋₃alkyl, -CO-N(R₁₄)R₁₅, carboxyl or an optionally substituted heterocyclic ring;

R₁₂ is hydroxy or -OR₁₆;

R₁₃ is hydrogen, straight-chained or branched C₁₋₆alkyl, straight-chained or branched C₂₋₆alkenyl, straight-chained or branched C₂₋₆alkynyl or a group of Formula (3):
 15



R₁₄ and R₁₅, which may be the same or different, are hydrogen, optionally substituted straight-chained or
 20 branched C₁₋₄alkyl, C₃₋₇cycloalkyl, straight-chained or branched C₁₋₄alkyloxy, straight-chained or branched C₁₋₄alkylsulfonyl or a heterocyclic ring, or R₁₄ and R₁₅, as -N(R₁₄)R₁₅, form optionally substituted 3- to 7-membered cyclic amine;

25 R₁₆ is straight-chained C₁₋₄alkyl;

R₁₇ is hydrogen or methyl;

R₁₈ and R₁₉ together form cycloalkyl or C₃₋₇cycloalkenyl;

X is carbonyl or methylene;

Y is carbonyl or methylene;

5 provided that

when Cy is 3-indolyl,

(i) R₁₁ is an optionally substituted heterocyclic ring; or

~~(ii) R₆ is hydrogen~~

10 R₉ is isopropyl, R₂₀ is hydrogen, R₁₀ is methyl, R₁₁ is carbamoyl, R₁₂ is hydroxy, R₁₃ is tert-butyl, X is carbonyl and Y is carbonyl, and

when Cy is cyclohexyl or phenyl, R₁₁ is an optionally substituted heterocyclic ring;

15 or a hydrate or pharmaceutically acceptable salt thereof.

09390219 121201